Further studies must assess whether the addition of parameters, e.g., anthracycline doses, tumor type, age, LV-EF etc. to the ECG score could further improve the prognostic accuracy of the score, especially for collectives like breast cancer patients undergoing high-dose anthracycline or anti-Her2 therapies. This evidence concerns the gene ERBB2 and neoplasm.